Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Auvelity: A New Era in Medicine - Unraveling the Multifaceted Benefits of Dextromethorphan/Bupropion Combination

Author(s): Anchal Dhawan, Sunayna Choudhary*, Sumeet Gupta, Abhishek Chander and Meenakshi Dhanawat

Volume 19, Issue 6, 2024

Published on: 21 September, 2023

Page: [628 - 637] Pages: 10

DOI: 10.2174/1574885519666230913105725

Price: $65

conference banner
Abstract

Background: Depression is a prevalent global illness, impacting 280 million people worldwide, and Major Depressive Disorder (MDD) is ranked as the third leading cause of disease burden globally. People previously diagnosed with depression are more likely to develop Alzheimer's disease (AD). The recent approval of Auvelity by the FDA has made a remarkable breakthrough in drug development, offering a multi-dimensional approach for managing multiple diseases.

Objective: The main objective of this study is to investigate the role of Auvelity, a new drug, in treating MDD and its potential to manage agitation in individuals with Alzheimer's disease (AD).

Methodology: Data on Auvelity was collected from various sources, including accessdata.fda.gov, PubMed, and Scopus, and compiled for analysis.

Discussion: Auvelity is the first oral medication to demonstrate the rapid onset of action, with statistically significant antidepressant efficacy observed as early as one week compared to a placebo. It contains a combination of dextromethorphan (45 mg) and bupropion (105 mg). The drug's mechanism of action involves a combination of NMDA receptor blockade and agonism of the sigma-1 receptor, resulting in the antagonization of the glutamatergic neurotransmitter pathway. Due to the similarity in the mechanism of action with AD medications like Memantine, there is a hypothesis that Auvelity could effectively reduce symptoms of AD.

Conclusion: The approval of Auvelity marks a significant advancement in depression treatment with its unique NMDA antagonist mechanism, rapid onset of action, and low-risk profile.

Keywords: Auvelity, Alzheimer’s disease, major depressive disorder, dextromethorphan, bupropion, dementia, antidepressants.

« Previous Next »
Graphical Abstract

[1]
Stahl SM. Dextromethorphan/Bupropion: A novel oral NMDA (N-methyl-d-aspartate) receptor antagonist with multimodal activity. CNS Spectr 2019; 24(5): 461-6.
[http://dx.doi.org/10.1017/S1092852919001470] [PMID: 31566163]
[2]
Juszczyk G, Mikulska J, Kasperek K, Pietrzak D, Mrozek W, Herbet M. Chronic stress and oxidative stress as common factors of the pathogenesis of depression and Alzheimer’s disease: The role of antioxidants in prevention and treatment. Antioxidants 2021; 10(9): 1439.
[http://dx.doi.org/10.3390/antiox10091439] [PMID: 34573069]
[3]
Edinoff AN, Swinford CR, Odisho AS, et al. Clinically relevant drug interactions with monoamine oxidase inhibitors. Health Psychol Res 2022; 10(4): 39576.
[http://dx.doi.org/10.52965/001c.39576] [PMID: 36425231]
[4]
Kalueff A. Tuohimaa PJAne. Experimental modeling of anxiety and depression. Acta Neurobiol Exp 2004; 64(4): 439-48.
[5]
Li Q, Wu Y, Chen J, Xuan A, Wang X. Microglia and immunotherapy in Alzheimer’s disease. Acta Neurol Scand 2022; 145(3): 273-8.
[http://dx.doi.org/10.1111/ane.13551] [PMID: 34779509]
[6]
Španić E, Langer Horvat L, Hof PR, Šimić G. Role of microglial cells in Alzheimer’s disease tau propagation. Front Aging Neurosci 2019; 11: 271.
[http://dx.doi.org/10.3389/fnagi.2019.00271] [PMID: 31636558]
[7]
Scheltens P, Blennow K, Breteler MMB, et al. Alzheimer’s disease. Lancet 2016; 388(10043): 505-17.
[http://dx.doi.org/10.1016/S0140-6736(15)01124-1] [PMID: 26921134]
[8]
Lee ATC, Richards M, Chan WC, Chiu HFK, Lee RSY, Lam LCW. Association of daily intellectual activities with lower risk of incident dementia among older chinese adults. JAMA Psychiatry 2018; 75(7): 697-703.
[http://dx.doi.org/10.1001/jamapsychiatry.2018.0657] [PMID: 29847678]
[9]
Ballard CG, Cassidy G, Bannister C, Mohan RNC. Prevalence, symptom profile, and aetiology of depression in dementia sufferers. J Affect Disord 1993; 29(1): 1-6.
[http://dx.doi.org/10.1016/0165-0327(93)90111-V] [PMID: 8254137]
[10]
Ballard C, Bannister C, Solis M, Oyebode F, Wilcock G. The prevalence, associations and symptoms of depression amongst dementia sufferers. J Affect Disord 1996; 36(3-4): 135-44.
[http://dx.doi.org/10.1016/0165-0327(95)00072-0] [PMID: 8821316]
[11]
Atri A. The Alzheimer’s disease clinical spectrum: Diagnosis and management. Med Clin North Am 2019; 103(2): 263-93.
[http://dx.doi.org/10.1016/j.mcna.2018.10.009] [PMID: 30704681]
[12]
Brodaty H, Luscombe G. Depression in persons with dementia. Int Psychogeriatr 1996; 8(4): 609-22.
[http://dx.doi.org/10.1017/S104161029600292X] [PMID: 9147174]
[13]
Beardmore R, Hou R, Darekar A, Holmes C, Boche D. The Locus Coeruleus in aging and Alzheimer’s disease: A postmortem and brain imaging review. J Alzheimers Dis 2021; 83(1): 5-22.
[http://dx.doi.org/10.3233/JAD-210191] [PMID: 34219717]
[14]
Lyketsos CG, Lee HB. Diagnosis and treatment of depression in Alzheimer’s disease. A practical update for the clinician. Dement Geriatr Cogn Disord 2004; 17(1-2): 55-64.
[http://dx.doi.org/10.1159/000074277] [PMID: 14564126]
[15]
Lyketsos CG, Olin J. Depression in Alzheimer’s disease: Overview and treatment. Biol Psychiatry 2002; 52(3): 243-52.
[http://dx.doi.org/10.1016/S0006-3223(02)01348-3] [PMID: 12182930]
[16]
Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: Findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000; 157(5): 708-14.
[http://dx.doi.org/10.1176/appi.ajp.157.5.708] [PMID: 10784462]
[17]
Kresin T, Hawgood J, De Leo D, Varghese F. Attitudes and arguments in the voluntary assisted dying debate in Australia: What are they and how have they evolved over time? Int J Environ Res Public Health 2021; 18(23): 12327.
[http://dx.doi.org/10.3390/ijerph182312327] [PMID: 34886053]
[18]
Laganà V, Bruno F, Altomari N, et al. Neuropsychiatric or behavioral and psychological symptoms of dementia (BPSD): Focus on prevalence and natural history in Alzheimer’s disease and frontotemporal dementia. Front Neurol 2022; 13: 832199.
[http://dx.doi.org/10.3389/fneur.2022.832199] [PMID: 35812082]
[19]
Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. JAMA 2002; 288(12): 1475-83.
[http://dx.doi.org/10.1001/jama.288.12.1475] [PMID: 12243634]
[20]
Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol 2012; 3: 73.
[http://dx.doi.org/10.3389/fneur.2012.00073] [PMID: 22586419]
[21]
Tetsuka S. Depression and dementia in older adults: A neuropsychological review. Aging Dis 2021; 12(8): 1920-34.
[http://dx.doi.org/10.14336/AD.2021.0526] [PMID: 34881077]
[22]
Botto R, Callai N, Cermelli A, Causarano L, Rainero I. Anxiety and depression in Alzheimer’s disease: A systematic review of pathogenetic mechanisms and relation to cognitive decline. Neurol Sci 2022; 43(7): 4107-24.
[http://dx.doi.org/10.1007/s10072-022-06068-x] [PMID: 35461471]
[23]
Wilson RS, Boyle PA, Yu L, et al. Temporal course and pathologic basis of unawareness of memory loss in dementia. Neurology 2015; 85(11): 984-91.
[http://dx.doi.org/10.1212/WNL.0000000000001935] [PMID: 26311746]
[24]
Remes O, Mendes JF, Templeton P. Biological, Psychological, and social determinants of depression: A review of recent literature. Brain Sci 2021; 11(12): 1633.
[http://dx.doi.org/10.3390/brainsci11121633] [PMID: 34942936]
[25]
Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: Systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006; 63(5): 530-8.
[http://dx.doi.org/10.1001/archpsyc.63.5.530] [PMID: 16651510]
[26]
van Sprang ED, Maciejewski DF, Milaneschi Y, et al. Familial risk for depressive and anxiety disorders: Associations with genetic, clinical, and psychosocial vulnerabilities. Psychol Med 2022; 52(4): 696-706.
[http://dx.doi.org/10.1017/S0033291720002299] [PMID: 32624018]
[27]
Albert PR. Why is depression more prevalent in women? J Psychiatry Neurosci 2015; 40(4): 219-21.
[http://dx.doi.org/10.1503/jpn.150205] [PMID: 26107348]
[28]
Wang H, Tian X, Wang X, Wang Y. Evolution and emerging trends in depression research from 2004 to 2019: A literature visualization analysis. Front Psychiatry 2021; 12: 705749.
[http://dx.doi.org/10.3389/fpsyt.2021.705749] [PMID: 34777037]
[29]
Olin JT, Schneider LS, Katz IR, et al. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry 2002; 10(2): 125-8.
[http://dx.doi.org/10.1097/00019442-200203000-00003] [PMID: 11925273]
[30]
Petersen IT, Bates JE, Goodnight JA, et al. Interaction between serotonin transporter polymorphism (5-HTTLPR) and stressful life events in adolescents’ trajectories of anxious/depressed symptoms. Dev Psychol 2012; 48(5): 1463-75.
[http://dx.doi.org/10.1037/a0027471] [PMID: 22390669]
[31]
Liu CC, Kanekiyo T, Xu H, Bu G, Bu G. Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol 2013; 9(2): 106-18.
[http://dx.doi.org/10.1038/nrneurol.2012.263] [PMID: 23296339]
[32]
Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer’s disease. Neuron 2009; 63(3): 287-303.
[http://dx.doi.org/10.1016/j.neuron.2009.06.026] [PMID: 19679070]
[33]
Salmon E, Perani D, Herholz K, et al. Neural correlates of anosognosia for cognitive impairment in Alzheimer’s disease. Hum Brain Mapp 2006; 27(7): 588-97.
[http://dx.doi.org/10.1002/hbm.20203] [PMID: 16247783]
[34]
Förstl H, Burns A, Luthert P, Cairns N, Lantos P, Levy R. Clinical and neuropathological correlates of depression in Alzheimer’s disease. Psychol Med 1992; 22(4): 877-84.
[http://dx.doi.org/10.1017/S0033291700038459] [PMID: 1488485]
[35]
Weinshenker D. Functional consequences of locus coeruleus degeneration in Alzheimer’s disease. Curr Alzheimer Res 2008; 5(3): 342-5.
[http://dx.doi.org/10.2174/156720508784533286] [PMID: 18537547]
[36]
Yiannopoulou KG, Papageorgiou SG. Current and future treatments in Alzheimer disease: An update. J Cent Nerv Syst Dis 2020; 12.
[http://dx.doi.org/10.1177/1179573520907397] [PMID: 32165850]
[37]
de Roten Y, Djillali S, Crettaz von Roten F, Despland JN, Ambresin G. Defense mechanisms and treatment response in depressed inpatients. Front Psychol 2021; 12: 633939.
[http://dx.doi.org/10.3389/fpsyg.2021.633939] [PMID: 33815219]
[38]
Zuin M, Cherubini A, Volpato S, Ferrucci L, Zuliani G. Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia. Sci Rep 2022; 12(1): 12214.
[http://dx.doi.org/10.1038/s41598-022-16476-w] [PMID: 35842477]
[39]
Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis. Clin Interv Aging 2008; 3(2): 211-25.
[PMID: 18686744]
[40]
Grover S, Raju VV, Sharma A, Shah R. Depression in children and adolescents: A review of Indian studies. Indian J Psychol Med 2019; 41(3): 216-27.
[http://dx.doi.org/10.4103/IJPSYM.IJPSYM_5_19] [PMID: 31142922]
[41]
Olivares D, Deshpande VK, Shi Y, et al. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer’s disease, vascular dementia and Parkinson’s disease. Curr Alzheimer Res 2012; 9(6): 746-58.
[http://dx.doi.org/10.2174/156720512801322564] [PMID: 21875407]
[42]
Haake A, Nguyen K, Friedman L, Chakkamparambil B, Grossberg GT. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opin Drug Saf 2020; 19(2): 147-57.
[http://dx.doi.org/10.1080/14740338.2020.1721456] [PMID: 31976781]
[43]
Pardo-Moreno T, González-Acedo A, Rivas-Domínguez A, et al. Therapeutic approach to Alzheimer’s disease: Current treatments and new perspectives. Pharmaceutics 2022; 14(6): 1117.
[http://dx.doi.org/10.3390/pharmaceutics14061117] [PMID: 35745693]
[44]
Li CT, Su TP, Cheng CM, Chen MH, Bai YM, Tsai SJ. Factors associated with antidepressant responses to repetitive transcranial magnetic stimulation in antidepressant-resistant depression. Front Neurosci 2022; 16: 1046920.
[http://dx.doi.org/10.3389/fnins.2022.1046920] [PMID: 36532273]
[45]
Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: From monoamines to glutamate. Exp Clin Psychopharmacol 2015; 23(1): 1-21.
[http://dx.doi.org/10.1037/a0038550] [PMID: 25643025]
[46]
Blanco C, Bragdon LB, Schneier FR, Liebowitz MR. The evidence-based pharmacotherapy of social anxiety disorder. Int J Neuropsychopharmacol 2013; 16(1): 235-49.
[http://dx.doi.org/10.1017/S1461145712000119] [PMID: 22436306]
[47]
Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: Rationale and current status of research. CNS Drugs 2013; 27(9): 703-16.
[http://dx.doi.org/10.1007/s40263-013-0071-0] [PMID: 23757185]
[48]
Mineur YS, Einstein EB, Bentham MP, et al. Expression of the 5-HT1A serotonin receptor in the hippocampus is required for social stress resilience and the antidepressant-like effects induced by the nicotinic partial agonist cytisine. Neuropsychopharmacology 2015; 40(4): 938-46.
[http://dx.doi.org/10.1038/npp.2014.269] [PMID: 25288485]
[49]
Bradbury S, Bird J, Colussi-Mas J, Mueller M, Ricaurte G, Schenk S. Acquisition of MDMA self-administration: Pharmacokinetic factors and MDMA-induced serotonin release. Addict Biol 2014; 19(5): 874-84.
[http://dx.doi.org/10.1111/adb.12069] [PMID: 23763615]
[50]
Faria M, Bellot M, Soto O, et al. Developmental exposure to sertraline impaired zebrafish behavioral and neurochemical profiles. Front Physiol 2022; 13: 1040598.
[http://dx.doi.org/10.3389/fphys.2022.1040598] [PMID: 36467683]
[51]
Chaurasiya N, Leon F, Muhammad I, Tekwani B. Natural products inhibitors of monoamine oxidases- potential new drug leads for neuroprotection, neurological disorders, and neuroblastoma. Molecules 2022; 27(13): 4297.
[http://dx.doi.org/10.3390/molecules27134297] [PMID: 35807542]
[52]
Zheng M, Fan Y, Shi D, Liu C. Antidepressant-like effect of flavonoids extracted from Apocynum venetum leaves on brain monoamine levels and dopaminergic system. J Ethnopharmacol 2013; 147(1): 108-13.
[http://dx.doi.org/10.1016/j.jep.2013.02.015] [PMID: 23453939]
[53]
Popovic D, Vieta E, Fornaro M, Perugi G. Cognitive tolerability following successful long term treatment of major depression and anxiety disorders with SSRi antidepressants. J Affect Disord 2015; 173: 211-5.
[http://dx.doi.org/10.1016/j.jad.2014.11.008] [PMID: 25462418]
[54]
Kerr GW, McGuffie AC, Wilkie S. Tricyclic antidepressant overdose: A review. Emerg Med J 2001; 18(4): 236-41.
[http://dx.doi.org/10.1136/emj.18.4.236] [PMID: 11435353]
[55]
Matias S, Lottem E, Dugué GP, Mainen ZF. Activity patterns of serotonin neurons underlying cognitive flexibility. eLife 2017; 6: e20552.
[http://dx.doi.org/10.7554/eLife.20552] [PMID: 28322190]
[56]
Hashimoto K. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochem Pharmacol 2020; 177: 113935.
[http://dx.doi.org/10.1016/j.bcp.2020.113935] [PMID: 32224141]
[57]
Madhukar HT, Ella JD. Treatment strategies to improve and sustain remission in major depressive disorder. Dialogues Clin Neurosci 2008; 10(4): 377-84.
[http://dx.doi.org/10.31887/DCNS.2008.10.4/mhtrivedi] [PMID: 19170395]
[58]
Stavrakaki C, Vargo B. The relationship of anxiety and depression: A review of the literature. Br J Psychiatry 1986; 149(1): 7-16.
[http://dx.doi.org/10.1192/bjp.149.1.7] [PMID: 3535981]
[59]
Majeed A, Xiong J, Teopiz KM, et al. Efficacy of dextromethorphan for the treatment of depression: A systematic review of preclinical and clinical trials. Expert Opin Emerg Drugs 2021; 26(1): 63-74.
[http://dx.doi.org/10.1080/14728214.2021.1898588] [PMID: 33682569]
[60]
Zawertailo LA, Kaplan HL, Busto UE, Tyndale RF, Sellers EM. Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: A pilot study. J Clin Psychopharmacol 1998; 18(4): 332-7.
[http://dx.doi.org/10.1097/00004714-199808000-00014] [PMID: 9690700]
[61]
Hysek CM, Simmler LD, Schillinger N, et al. Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. Int J Neuropsychopharmacol 2014; 17(3): 371-81.
[http://dx.doi.org/10.1017/S1461145713001132] [PMID: 24103254]
[62]
Keam SJ. Dextromethorphan/Bupropion: First approval. CNS Drugs 2022; 36(11): 1229-38.
[http://dx.doi.org/10.1007/s40263-022-00968-4] [PMID: 36301443]
[63]
Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpé S, Maes M. IDO and interferon-α-induced depressive symptoms: A shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005; 10(6): 538-44.
[http://dx.doi.org/10.1038/sj.mp.4001600] [PMID: 15494706]
[64]
Dobson KSJCPR. The relationship between anxiety and depression. Clin Psychol Rev 1985; 5(4): 307-24.
[http://dx.doi.org/10.1016/0272-7358(85)90010-8]
[65]
Kendall PC, Watson DE. Tripartite model of anxiety and depression: Psychometric evidence and taxonomic implications. J Abnorm Psychol 1989; 100(3): 316-36.
[66]
Khabir Y, Hashmi MR, Asghar AA. Rapid-acting oral drug (Auvelity) for major depressive disorder. Ann Med Surg 2022; 82: 104629.
[http://dx.doi.org/10.1016/j.amsu.2022.104629] [PMID: 36268350]
[67]
Zhang A, Borhneimer LA, Weaver A, et al. Cognitive behavioral therapy for primary care depression and anxiety: A secondary meta-analytic review using robust variance estimation in meta-regression. J Behav Med 2019; 42(6): 1117-41.
[http://dx.doi.org/10.1007/s10865-019-00046-z] [PMID: 31004323]
[68]
Mathews DC, Henter ID, Zarate CA Jr. Targeting the glutamatergic system to treat major depressive disorder: Rationale and progress to date. Drugs 2012; 72(10): 1313-33.
[http://dx.doi.org/10.2165/11633130-000000000-00000] [PMID: 22731961]
[69]
Ballard C, Neill D, O’Brien J, McKeith IG, Ince P, Perry R. Anxiety, depression and psychosis in vascular dementia: Prevalence and associations. J Affect Disord 2000; 59(2): 97-106.
[http://dx.doi.org/10.1016/S0165-0327(99)00057-9] [PMID: 10837878]
[70]
Tiller JWG. Depression and anxiety. Med J Aust 2013; 199(S6): S28-31.
[http://dx.doi.org/10.5694/mja12.10628] [PMID: 25370281]

Rights & Permissions Print Cite
Article Metrics
15
1
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy